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abstract
The essential package of palliative care for cervical cancer (EPPCCC), described elsewhere, is designed to be
safe and effective for preventing and relieving most suffering associated with cervical cancer and universally
accessible. However, it appears that women with cervical cancer, more frequently than patients with other
cancers, experience various types of suffering that are refractory to basic palliative care such as what can be
provided with the EPPCCC. In particular, relief of refractory pain, vomiting because of bowel obstruction,
bleeding, and psychosocial suffering may require additional expertise, medicines, or equipment. Therefore, we
convened a group of experienced experts in all aspects of care for women with cervical cancer, and from
countries of all income levels, to create an augmented package of palliative care for cervical cancer with which
even suffering refractory to the EPPCCC often can be relieved. The package consists of medicines, radiotherapy,
surgical procedures, and psycho-oncologic therapies that require advanced or specialized training. Each item in
this package should be made accessible whenever the necessary resources and expertise are available.
JCO Global Oncol 7:886-895. © 2021 by American Society of Clinical Oncology
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INTRODUCTION
Cervical cancer, the fourth most common cancer in
women globally and the most common cause of
cancer-related death in sub-Saharan Africa,1 is as-
sociated with suffering that is more prevalent, com-
plex, and severe than that associated with other
malignancies.2,3 Elsewhere, we reported that women
with cervical cancer have a higher prevalence of
moderate or severe pain, anxiety, and depression than
patients with cancer on average.2 They also suffer from
a high prevalence of moderate or severe malodorous
vaginal discharge, bleeding, sexual dysfunction, and
financial distress, and more than 40% are abandoned
by their intimate partners.2 In light of this extraordi-
narily prevalent, severe, and complex suffering, we
convened a panel of experts in treatment and palliative
care of women with cervical cancer to devise an es-
sential package of palliative care for cervical cancer
(EPPCCC).3
The EPPCCC, described elsewhere and summarized
in Table 1, is designed to be the minimum package
that can safely and effectively prevent and relieve most
suffering associated with cervical cancer, to be
applicable by any clinicians with basic palliative care
training, and to be inexpensive enough to be made
universally accessible free of charge to the patient
even in the lowest-income settings.3 However, both
available evidence and expert opinion suggest that
cervical cancer frequently results in suffering too se-
vere, complex, or refractory to be adequately relieved
by basic palliative care.8-11 A variety of anatomic,
physiologic, psychological, and social factors appear
to contribute to this phenomenon. For example, the
proximity of major nerve plexuses to the cervix makes
them susceptible to tumor invasion that often results in
severe or refractory neuropathic pain.8,12 The large
blood supply to the uterus and vagina puts patients
with cervical cancer at risk of difficult-to-control
hemorrhage,13-15 and disruption by necrotic tumor
of the vaginal microbial environment often results in
difficult-to-treat, psychosocially disabling vaginal
discharge.15,16 The proximity of the cervix to bowel and
bladder puts patients at risk for bowel obstruction with
resultant intractable vomiting; rectovaginal, ves-
icovaginal, and enterovesical fistulae with distressing
leakage of stool and urine; and hydronephrosis with
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be palliated best by surgical procedures.17 Severe psy-
chosocial suffering that is difficult to relieve may result
when invasive cervical cancer or its treatment injures the
genitals and causes sexual dysfunction.18,19
These data suggest that women with cervical cancer often
experience suffering too severe, complex, or refractory to be
controlled by basic palliative care. Thus, the group of ex-
perienced experts in cervical cancer treatment and palli-
ation from countries of all income levels that created the
EPPCCC agreed that an augmented package was neces-
sary as a supplement to the EPPCCC. The augmented
package includes the following:
1. Palliative radiotherapy
2. Advanced medical therapies
3. Nerve blocks for pain control
4. Palliative surgery
5. Psycho-oncology.
Governments should assure that the EPPCCC is universally
accessible before approving even partial insurance cov-
erage of expensive elements of the augmented package for
which the poor may be unable to afford the co-payment.
However, all governments should aspire to make acces-
sible as much as possible of the augmented package as
soon as possible. Implementation of each element of the
augmented package requires advanced or specialist
training in one or more of several disciplines: palliative care,
radiation oncology, pain medicine, surgery, or psychiatry.
Thus, the effort to make the augmented package acces-
sible must entail efforts to create capacity for training in
these disciplines wherever it is inadequate or nonexistent.
Implementation of both packages will benefit not only
women with cervical cancer but also patients with any
serious illness.
PALLIATIVE RADIATION THERAPY
Patients with cervical cancer in low- and middle-income
countries (LMICs) frequently present with locally advanced
disease and associated symptoms.20,21 For these patients,
palliative external beam radiation therapy (EBRT) often can
provide rapid relief of vaginal bleeding or discharge and of
pain because of the primary lesion, nodal disease, or
metastatic disease in the mediastinum, neck, bone, or
brain.22 Yet radiotherapy often is difficult or impossible to
access in LMICs. Thus, making EBRT universally acces-
sible with simple, reliable machines is crucial to fulfill the
human right of patients with cancer to the highest attain-
able standard of health.23
The most common palliative EBRT regimens for symp-
tomatic pelvic cancers are shown in Table 2. They are
ordered frommost commonly used to least commonly used
globally. Choice of regimen should be based on the pa-
tient’s prognosis, specific symptoms, performance status,
ability to attend the radiotherapy center, and capacity of the
treating center.22,26,32,33 Short regimens, such as 3.7 Gy
twice daily for four fractions and up to three courses or 4-5
Gy daily for five fractions, are favored to balance effective
symptom palliation with minimum logistical burden for
patients, particularly when the prognosis may be limited.
Conventional palliative regimens, such as 3 Gy for 10
fractions, are also safe and effective. However, they may be
more burdensome for both patients and treatment centers
and do not offer better symptom response. Single treatment
regimens, such as 10 Gy for one fraction, offer convenience
but have higher toxicity.
Ideally, radiotherapy clinics should be distributed widely
enough to assure universal access and should be officially
and operationally integrated with comprehensive palliative
care services.34-36 Living accommodations should be made
available for patients who must spend one or more nights at
the radiotherapy facility. All radiation oncologists should
have intermediate-level palliative care training, at least 60
hours per WHO recommendation, to promote this inte-
gration and to help assure an appreciation for the full
spectrum of palliative interventions.37 Conversely, all levels
CONTEXT
Key Objective
Existing evidence indicates that patients with cervical cancer, more often than patients with other cancers, experience
suffering that is refractory to basic palliative care such as what can be provided with an essential package of palliative care
for cervical cancer. Therefore, a panel of experts in all aspects of cervical cancer treatment and palliation created an
augmented package of palliative care for cervical cancer intended to make possible relief even of refractory suffering.
Knowledge Generated
The augmented package of palliative care for cervical cancer consists of carefully selected medicines, radiotherapy, nerve
blocks, surgical procedures, and psycho-oncologic therapies that require advanced or specialized training. Each item in
this package should be made accessible whenever the necessary resources and expertise are available.
Relevance
The augmented package of palliative care for cervical cancer will make possible relief of many types of severe, refractory
suffering due not only to cervical cancer but also any cancer or serious illness.
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of palliative care training should include instruction on
indications for radiotherapy.38 Available evidence indicates
good economic return on investment in radiation therapy in
LMICs, especially for cervical cancer.36,39
ADVANCED MEDICAL THERAPIES
In addition to the medicines in the EPPCCC, several others
can significantly improve comfort of women in specific
clinical situations such as advanced-stage kidney disease
or neuropathic pain refractory to all other medicines in the
EPPCCC.4,6 Some of these medicines are more expensive
than those in the EPPCCC, and others are not as well-
studied, but they should be made accessible whenever
possible for patients with these conditions. However,
morphine in oral fast-acting and injectable preparations
should be accessible to everyone in need before any more
expensive opioid preparations are made available.40
Lidocaine, Injectable
For moderate or severe pain that is refractory to opioids, or
when opioids cause intolerable adverse effects, particularly
near the end of life, an intravenous bolus (1-2 mg/kg over
30 minutes) can be given.41,42 If the bolus provides relief, a
continuous infusion can be started (0.5-2 mg/kg/h) to maintain
TABLE 1. Essential Package of Palliative Care for People Affected by Cervical Cancer
Interventions Medicinesa Equipment Social Supportsb Human Resourcesc
1. Prevention and relief of
pain or other physical
suffering,d acute or
chronic




3. Prevention and relief of
social suffering, acute
or chronic






Diazepam, oral and injectable
Diphenhydramine
(chlorpheniramine, cyclizine,





Furosemide, oral and injectable











Metronidazole, oral (for both oral

























batteries (if no access
to electricity)
Adult diapers or cotton
and plastic
Cash transfers or resource
allocation for housing, children’s
school tuition, transportation to
health care facilities, or funeral
costs.
Other resource allocation (in-kind
support): food packages,
blankets, sleeping mats, shoes,
soap, toothbrushes, and
toothpaste
Doctors and clinical officers




(with basic palliative care
training)












Abbreviations: CHW, community health worker; PTSD, post-traumatic stress disorder.
aOn the basis of the WHO Model List of Essential Medicines 2019.7 Acceptable alternative medicines are in parentheses.
bAt least for patients living in extreme poverty and for one caregiver per patient.
cDoctors may be oncologists, gynecologists, surgeons, general practitioners, family doctors, clinical officers or assistant doctors, or others.
dOther physical suffering includes breathlessness, weakness, nausea, vomiting, diarrhea, constipation, incontinence, malodorous vaginal discharge, and
bleeding.
ePsychological suffering includes anxiety, depressed mood, PTSD, confusion or delirium, sexual dysfunction, and complicated grief.
fOnly in hospitals that provide cancer chemotherapy or radiotherapy.
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analgesia. The common side effects are usually mild or self-
limited and dose-related and include perioral numbness, se-
dation, confusion, lightheadedness, and headache. Cardiac
arrhythmia is a potential serious but low-risk adverse effect.
Lidocaine can be combined with opioids as needed.
Ketamine, Oral or Injectable
For moderate or severe pain that is refractory to opioids, or
when effective opioid doses cause intolerable adverse ef-
fects, ketamine can be added to enable reduction of opioid
dose and improve analgesia.8,43-51 A typical starting dose is
2.5 mg orally or intravenously every 8 hours. If there is no
benefit and also no adverse effect, the dose can be doubled
on day 2 and again on day 3. Themaximum dose is 0.5 mg/
kg/dose. It can also be given as an intravenously infusion at
0.05-0.3 mg/kg/h. Contraindications include uncontrolled
hypertension or high stroke risk. There is some evidence
that ketamine can be used safely in patients with increased
intracranial pressure and psychiatric illness.
Slow-Release Oral Morphine
For patients with moderate or severe cancer pain that is
frequent or constant who can take oral medicines, slow-
release oral morphine can reduce pill burden and provide
more steady relief.
Fentanyl Transdermal Patches
This opioid preparation generally is better than morphine to
treat moderate or severe cancer pain in noncachectic
patients whose opioid requirement is stable and who are
unable to take oral medicines or who have renal failure.
Fentanyl, Injectable
This is useful as a continuous infusion, with rescue bolus
doses as needed, for moderate or severe pain that is fre-
quent or constant in patients with renal failure or cachexia
who are unable to take oral medicines. It is also useful for
dose finding in noncachectic patients before applying
fentanyl transdermal patch. Because of the rapid onset of
action and short duration of action of injectable fentanyl,
bolus doses alone are a good choice for preventing pain
from brief procedures or dressing changes.
Injectable lidocaine, ketamine, and fentanyl are for use
mainly in hospitals, but they can be provided in the home
by palliative care specialist doctors if permitted by law and if
clinically indicated.
Besides morphine and fentanyl, the other strong opioid on
the WHO Model List of Essential Medicines for Pain and
Palliative Care 2019 is methadone.7 Although methadone
often can provide better relief for neuropathic pain than other
opioids, we did not include it in the augmented package
because opioid-refractory neuropathic pain can also be
treated with other medicines in the essential and augmented
packages, because of the relative complexity of its safe use,
and so as not to risk complicating extremely important efforts
in LMICs to use it to treat opioid use disorder.
NEUROLYTIC PROCEDURES FOR RELIEF OF SEVERE OR
REFRACTORY PAIN
Pain impulses from the pelvic region are transmitted via so-
matic nerves from muscle, bone, skin, and connective tissue
and via sympathetic and parasympathetic nerves and plexuses
from visceral organs.Neurolytic procedures, and in somecases
also neural stimulation, often can interrupt or modulate pain
impulses transmitted within this neural network.52-54 However,
because of the complexity of this pain network, adequate relief
often requires multimodal treatment such as with both a
neurolytic procedure and systemic pharmacotherapy.
Nerve Blocks
Neurolysis is the targeted destruction of a nerve or nerve
plexus with chemical agents (alcohol or phenol), heat
TABLE 2. Comparison of Palliative External Beam Radiation Therapy Regimens for Pelvic Cancers With Reported Rates of Symptom Control
Regimen Repeated Treatments Modality Symptom Control Rates
3.7 Gy twice a day × 4 fx, once every 2-4 weeks × up to three
courses24,25
Yes, 59% compliance on trial 2D or 3D ORR 45%
Bleeding 58%-75%
Pain 98%
4-5 Gy × 5 fxa,26 No 2D or 3D Bleeding 94%
Pain 67%
4.5 Gy twice a day × 4 fx27,28 No 3D ORR 89%
Bleeding 100%
Pain 93%
3 Gy × 10 fxa,29 No 2D or 3D Bleeding 88%
Pain 65%
10 Gy × 1 fx, monthly × up to 3 fx (10-by-3)30,31 Yes, 47% compliance in LMICs 2D or 3D ORR 62%
Bleeding 100% (third fx)
Pain 41% (second fx)
Vaginal discharge 29%
(second fx)
Abbreviations: fx, fraction (treatment); LMICs, low- and middle-income countries; ORR, overall response rate.
aRetrospective study.
Augmented Package of Palliative Care for Cervical Cancer
JCO Global Oncology 889
Downloaded from ascopubs.org by The Aga Khan University on July 24, 2021 from 058.027.240.066
Copyright © 2021 American Society of Clinical Oncology. See https://ascopubs.org/go/authors/open-access for reuse terms.
(radiofrequency ablation), or cold (cryoablation). If the
appropriate and adequately trained staff member(s) and
necessary equipment are available, these procedures
should be considered when pharmacologic pain treatment
results in inadequate pain control or intolerable side effects.
Typically, neurolytic blocks should be performed with
fluoroscopic, ultrasonographic, or computed tomography
guidance. Although these procedures are not effective for
every patient, they usually provide some degree of anal-
gesia, from partial to complete, that lasts from days to
several months and reduces the opioid requirement.55-57
Neurolysis of the superior hypogastric plexus is the most
common block for pelvic cancer pain. The superior hy-
pogastric plexus lies anterior to the L5/S1 disk and in-
nervates the cervix, uterus, bladder, and rectum.
Complications such as neural injury, bowel perforation,
retroperitoneal bleeding, bowel and bladder dysfunction,
infection, and diarrhea are rare.30,55-57
Ganglion impar block is a safe and relatively easy procedure
to treat visceral pelvic, perineal, and anal pain. The gan-
glion impar lies in the presacral space near the sacro-
coccygeal ligament and provides innervation to the
perineum, distal rectum, distal urethra, vagina, and vulva.
Image-guided neurolysis of the ganglion impar appears to
be a generally safe and effective procedure.58-60
Intrathecal drug delivery systems infuse analgesics directly
into the spinal fluid at the appropriate spinal level via a
subcutaneous catheter connected to an implanted, refill-
able drug pump. This method of analgesia can be very
effective but is expensive, requires specialized equipment
and well-trained staff members, and should not be initiated
during an infection.61-63 Because of the risk of permanent
neurologic injury, intrathecal saddle neurolysis of the sacral
nerve roots should be considered only as a last resort for
severe refractory pain in a patient near the end of life.64-66
Neurosurgical Procedures
Where a skilled spine surgeon and the necessary support
staff and facilities are available, transmission of pain im-
pulses from pelvis to brain can also be interrupted by
surgical intervention in the spine or brain.67 Chemical
rhizotomy (severing of spinal nerve roots) by injecting al-
cohol into the lumbar subarachnoid space can be com-
bined with percutaneous cordotomy,68 but skill and
expertise are necessary to minimize risk of injury to other
nerves. Another surgical option is to open the lumbar dura
and cut the dorsal roots to the pelvis.69 For pelvic pain
mainly on one side, the spinothalamic tract on the con-
tralateral side of the spinal cord can be interrupted by an
open surgical or percutaneous cordotomy. Cordotomy
usually is performed only unilaterally because bilateral
cordotomy has a high risk of permanent motor
weakness.70-72
A visceral afferent nociceptive pathway is located between
the dorsal columns of the spinal cord and can be
interrupted by surgical laminectomy and midline
myelotomy.73,74 This requires opening the spinal dura,
usually at the T10 level, direct incision into the dorsal
midline of the spinal cord between the dorsal columns over
1-2 cm in length, and extending within the spinal cord to
the level of the central canal—about 5 mm deep. An op-
erating surgical microscope is required to guide the incision
and minimize damage to the dorsal columns, which are
essential for balance and ambulation.75-78 There is some
risk of meningitis with this procedure, and it should be
performed only by well-trained and experienced
neurosurgeons.
The neural pathways that interpret pain in the brain can
also be interrupted by performing a stereotactic
cingulotomy.79 This procedure requires access to a ste-
reotactic frame and imaging to target the appropriate region
of the brain. Good pain relief at three months has been
reported in 64% of patients. Spinal cord stimulation, used
primarily for non-cancer pain, can also be used for cancer
pain. However, stimulators require surgical implantation
and are expensive, and the wire leads tend to break.53,80
Palliative Surgical Procedures
Women with locally advanced or recurrent invasive cervical
cancer may benefit from surgical procedures to palliate
physical symptoms and emotional distress related to
compromise of the urinary tract, intestinal tract, or vas-
culature. However, when deciding whether to intervene
surgically, the potential benefits of the surgery must be
weighed carefully against the risks and potential discom-
forts of the procedure itself in the context of the patient’s
values and likely prognosis. Women who are medically
fragile or are late in the course of their illness may be better
served by non- or less-invasive interventions.
Ureteral obstruction often causes pain and acute kidney
injury and can lead rapidly to destruction of function of one
or both kidneys. If possible, this should be treated with
placement of ureteral stents or, if necessary, percutaneous
nephrostomy tubes. Fistulae of the distal urinary tract to the
vagina or rectum may develop either because of direct
tumor infiltration or as a complication of radiotherapy.
Placement of flexible percutaneous nephrostomy tubes,
ideally with simultaneous placement of coils in the ureters,
can decrease or eliminate leakage of urine via a fistula from
the vagina or rectum. However, provision must be made for
urostomy bags.
The sigmoid colon or rectum can also become obstructed
because of infiltration or compression by tumor, and fis-
tulae can develop to the vagina or bladder. Colostomy can
relieve large bowel obstruction and may decrease or
eliminate fecal incontinence because of leakage via a fis-
tula. It also may help prevent abscess formation or enable
an existing abscess to heal after drainage and antibiotic
treatment. In addition, some women may experience ul-
ceration of the rectum as a complication of radiotherapy,
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and colostomy may bring relief from any resulting pain,
fecal frequency, or incontinence. Access to training in
colostomy care and to an adequate supply of colostomy
bags should be assured if colostomy is offered.
Local progression of cervical cancer may lead to cata-
strophic hemorrhage from compromise of major vessels or
from tumor neovasculature. If the goal of care is not solely
comfort but (also) to sustain life to some extent, emergent
selective pelvic vessel embolization should be considered if
experienced operators and adequate equipment are
available.14 If this is not an option, emergent palliative ra-
diotherapy should be arranged, if possible. If neither em-
bolization nor radiotherapy are available, tranexamic acid
can be given, and the vagina can be tightly packed with
simple roller gauge in a lithotomy position, with or without
sedation or short general anesthesia depending on ex-
pected pain. A bladder catheter is needed while the pack is
in place.81 If the only goal of care is comfort and the patient
appears to be exsanguinating, pain, dyspnea, anxiety, or
any other symptoms should be treated aggressively, even to
the point of sedation if necessary to assure comfort.
Psycho-Oncology
Any doctor with basic palliative care training should be able
to diagnose and treat uncomplicated anxiety or depressed
mood with medicines in the EPPCCC, described
elsewhere,3 and in LMICS, nurses, psychologists, social
workers, and community health workers can be trained to
provide simple, culturally appropriate supportive counsel-
ing and psychotherapy for uncomplicated depression.82-84
However, psychiatric or psycho-oncologic consultation is
recommended for severe or refractory symptoms, for pa-
tients taking multiple psychoactive medicines, and for more
complex psychiatric disorders such as bipolar disorder and
psychotic disorders.85,86
Psycho-oncology, a subspecialty of psychiatry and psy-
chology, addresses the psychological, social, behavioral,
and cognitive problems related to cancer and cancer
treatment. Psycho-oncologists collaborate with oncologists
and palliative care providers to assess severe, complex, or
refractory psychological and social suffering of patients with
cancer and their family members and to plan and
implement efforts to relieve this suffering.87,88 Specific
competencies include diagnosis of psychological distress
and comorbidities such as anxiety disorders, post-
traumatic stress disorder, major depression, and sexual
dysfunction; recognition of drug interactions and adverse
psychological effects such as delirium; planning and
implementing evidence-based psychopharmacologic and
nonpharmacologic interventions; assistance with difficult
discussions with patients or family members; and identi-
fication of optimum goals of care.85-87
Standard open-access measures used by psycho-
oncologists to identify and diagnose psychosocial distress
include the Distress Thermometer,89 the Patient Health
Questionnaire Anxiety and Depression Scale,90 and the
PROMIS emotional distress scales for cervical cancer.91
Treatment is tailored to the specific clinical situation.
Evidence-based nonpharmacologic interventions for anxi-
ety and depression include cognitive behavioral therapy,
acceptance and commitment therapy, psychoeducation,
and mindfulness and relaxation.87,92 Some patients benefit
from existential interventions, such as dignity therapy, that
promote meaning making, foster hope, and support ex-
pression of feelings at the end of life.93 Psycho-oncologists
who are psychiatrists (medical doctors) can provide advice
on the best pharmacologic interventions in a specific sit-
uation. Specialized psycho-oncologic consultation can be
made accessible in LMICs via mobile phone or internet
either as needed or as part of regular virtual tumor board
conferences.
In conclusion, cervical cancer and its treatment sometimes
result in suffering that is refractory to basic palliative care
with the EPPCC. Therefore, we propose an augmented
package of palliative care for cervical cancer that can
prevent or alleviate even refractory suffering. Some ele-
ments require special training or experience, and some
medicines or equipment are expensive and will not be
widely available in low-income settings. However, we
propose that each element should be implemented as soon
as possible by at least one referral center in a region,
province, or state, in a manner that makes relief of re-
fractory suffering accessible by all.
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10Université Episcopale d’Haiti, Port-au-Prince, Haiti
11Faculté des Sciences Infirmières de Leogane, Léogâne, Haiti
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